论文部分内容阅读
目的观察紫杉醇注射液联合奈达铂注射剂治疗晚期复发转移性宫颈癌的临床疗效及安全性。方法将45例晚期复发转移性宫颈癌患者均予以静脉滴注150 mg·m~(-2) 紫杉醇,第1天+静脉滴注80 mg·m~(-2) 奈达铂,第1天。观察患者的近期疗效、药物不良反应发生情况及预后情况。结果治疗后,在45例患者中完全缓解3例(6.67%),部分缓解21例(46.67%),稳定10例(22.22%),进展11例(24.44%),客观缓解率为53.33%(24/45例)。末次化疗时间距本次治疗时间(>12个月或≤12个月)的临床近期疗效分别为20.00%(3/15例)和80.95%(17/21例),差异有统计学意义(P<0.05)。中位总体生存时间为13.90个月,死亡42例。COX单因素分析显示,入组前是否接受过放疗、入组前是否接受过化疗以及末次化疗距本次治疗时间的中位总体生存时间差异均无统计学意义(均P>0.05)。药物不良反应主要表现为骨髓抑制、胃肠道反应、乏力和周围神经感觉异常。结论紫杉醇注射液联合奈达铂注射剂治疗晚期复发转移性宫颈癌的临床疗效显著,安全性高。
Objective To observe the clinical efficacy and safety of paclitaxel injection combined with nedaplatin in the treatment of advanced recurrent cervical cancer. Methods Forty-five patients with advanced recurrent cervical cancer were treated with intravenous drip of paclitaxel (150 mg · m -2) and intravenous drip (80 mg · m -2) of nedaplatin on the first day. On the first day . To observe the short-term efficacy of patients, the incidence of adverse drug reactions and prognosis. Results After the treatment, 3 cases (6.67%) were completely relieved in 45 cases, 21 cases (46.67%) were partly relieved, 10 cases (22.22%) were stabilized, 11 cases (24.44%) were progressing and the objective response rate was 53.33% 24/45 cases). The short-term clinical efficacy of the last chemotherapy was 20.00% (3/15 cases) and 80.95% (17/21 cases), respectively, with a significant difference from the current treatment time (> 12 months or ≤12 months) <0.05). The median overall survival was 13.90 months, 42 deaths. COX univariate analysis showed that there was no significant difference in the median overall survival time between the last treatment and the last chemotherapy after receiving radiotherapy before enrollment or before enrollment (all P> 0.05). Adverse drug reactions mainly manifested as myelosuppression, gastrointestinal reactions, fatigue and peripheral nerve sensory abnormalities. Conclusion paclitaxel injection combined with nedaplatin injection for the treatment of advanced recurrent cervical cancer with significant clinical efficacy and safety.